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Aim To evaluate the existing evidence on relative effica-
cy and tolerability of topical mono-compound intraocular 
pressure (IOP)-lowering drugs in treatment of primary open 
angle glaucoma (POAG) and ocular hypertension (OHT).
Methods In this systematic review of systematic reviews/
meta-analyses of randomized controlled trials a thorough 
and sensitive search of PubMed, Embase and Cochrane 
Databases was performed. Individual study methodologi-
cal quality and quality of evidence were assessed using 
the AMSTAR checklist and the GRADE system, respectively. 
The relationships between individual drugs were evaluated 
based on the best available evidence.
Results Of the 133 initial non-duplicate records, 16 stud-
ies met the inclusion criteria. Five achieved an overall 
“moderate” (none achieved “high”) quality of evidence and 
evaluated prostaglandin analogues (PGAs) – latanoprost, 
travoprost, and bimatoprost; timolol; “other beta-blockers;” 
carbonic anhydrase inhibitors (CAI) as a group or dorzol-
amide separately; and brimonidine. “Moderate quality” re-
fers to efficacy and incidence of conjunctival hyperemia. 
Quality of evidence regarding other tolerability aspects was 
low. PGAs should be considered equivalent regarding ef-
ficacy, but latanoprost was relevantly better tolerated than 
the other two. Non-PGA compounds did not relevantly dif-
fer between each other in either efficacy or safety. Timolol 
and brimonidine were relevantly less effective than all PGAs. 
The same was true for CAI vs bimatoprost. Regarding tolera-
bility, timolol was superior to all PGAs and brimonidine and 
CAI were superior to bimatoprost.
Conclusion No high quality evidence on relative efficacy 
and tolerability of the most commonly used mono-com-
pound IOP-lowering drugs for POAG/OHT exists. Moderate 
quality evidence indicates latanoprost as a treatment with 
the most favorable trade-off between benefits and harms.
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Glaucoma subsumes a group of optic neuropathies with 
different causes and pathophysiological mechanisms that 
can permanently damage vision in the affected eye if left 
untreated (1,2). It is the leading cause of irreversible blind-
ness worldwide (2-5). Depending on the mechanism of 
aqueous outflow impairment with respect to the anteri-
or chamber angle configuration, glaucoma is classified as 
open or closed angle glaucoma. Open angle glaucoma 
(OAG) is by far more common (75%) and it is estimated that 
by the year 2020 it will affect 60 million people worldwide 
(2,4). Depending on the presence or absence of ocular or 
systemic disorders, OAG is classified as primary or second-
ary, with the primary form (POAG) prevailing. POAG is most 
commonly characterized by increased intraocular pressure 
(IOP), but IOP could also be consistently “normal”, ie, within 
±2-3 standard deviations of an average “normal” value (6). 
Consequently, it is denoted as “high-tension” POAG (POAG-
HTG) or as “normal-tension” POAG (POAG-NTG). In any case, 
it is a progressive chronic optic neuropathy in the absence 
of identifiable causes, where IOP and other unknown fac-
tors contribute to the loss of retinal ganglionic cells (RGCs) 
and their axons (7-9). When IOP is elevated but there is no 
detectable glaucomatous damage, the condition is called 
ocular hypertension (OHT) (8). Damage to the optical nerve 
is usually slow, and if treated, most patients retain useful vi-
sion for their entire lives. Therapeutic aim is to prevent im-
pairment of vision by slowing down the apoptosis of RGCs. 
Different treatment modalities targeting factors that may 
play a role in POAG pathogenesis are being investigated 
(10-12) but for the time being, the only modality recom-
mended by the professional guidelines is IOP-lowering 
treatment (7,8). Reduction of IOP prevents both conversion 
of OHT to POAG and progression of POAG (13-16), and can 
be achieved by medications, laser, or surgical therapy. Topi-
cal drug therapy is a standard initial intervention, where-
as the latter two options are implemented mainly when 
conservative therapy is not effective, not tolerated, or not 
utilized by the patient (7-9). There are five major classes of 
IOP-lowering compounds, each comprising several indi-
vidual drugs, and also a large number of their fixed combi-
nations. They lower IOP by reducing aqueous production 
or/and by increasing aqueous outflow (7,17-20). According 
to the guidelines, IOP-lowering treatment should start with 
a mono-compound therapy and should aim to reduce IOP 
by 20%-30%. A rational first line mono-compound drug is 
the one installed as infrequently as possible for the thera-
peutic effect and with the fewest side-effects (7,8). If the 
first line medication is not effective or not tolerated it could 
be substituted, another drug may be added (unfixed com-
bination), or a patient could be switched to a fixed com-
bination of different compounds (8,17,18). A recent com-
prehensive evaluation (9,21) demonstrated a high level 
of evidence of efficacy in IOP reduction of various topical 
pharmacological treatments but with some uncertainty re-
garding their mutual relationship in this respect. The lat-
ter was in part due to inconsistent results of some studies 
and to the complexity of the setting (eg, different forms of 
OAG, treatment-naďve/previously unsuccessfully treated 
patients) and treatment modalities (mono-compounds, 
fixed/unfixed combinations) (9,21). We aimed to evaluate 
the existing evidence on relative efficacy and tolerability 
of mono-compound topical medications (recommended 
as initial treatment options) in POAG and OHT, the most 
common conditions requiring IOP-reducing therapy. Since 
by the year 2010 there were already 112 systematic reviews 
published on various aspects of glaucoma (22), of which 
at least 20 addressed medical treatments (23), we decid-
ed to perform an overview of systematic reviews, as they 
are generally considered a (potential) source of the highest 
level of evidence about therapeutic interventions.
MaTerials anD MeThoDs
We performed an overview of systematic reviews/meta-
analyses of randomized controlled trials (RCTs) of IOP-low-
ering mono-compound treatments in patients with POAG 
and/or OHT. The PRIMSA statement (24) and the current 
Cochrane Handbook for Systematic Reviews (Version 5.1.0, 
2011) (25) were consulted for evaluation of reporting and 
technical aspects of the included reviews. The overview of 
reviews followed the format suggested by the Cochrane 
Handbook (25).
search strategy
The initial search was conceived to be sensitive, not spe-
cific, hence no restrictions were set. We searched electronic 
databases – PubMed, Embase, and all Cochrane Databases 
(Cochrane Database of Systematic Reviews, Health Technol-
ogy Assessment Database, Database of Abstracts of Reviews 
of Effects) – till January 31, 2014 and performed a further 
search of reference lists of relevant publications. In PubMed, 
“clinical queries” and “related articles” functions were used 
to broaden the search. Direct search terms and controlled 
terms were adjusted to each database. To identify study de-
sign, we used “systematic review,” “meta-analysis,” “RCT;” to 
identify the health condition, we used “glaucoma,” “open 
angle glaucoma,” “ocular hypertension;” and to search for 
medications, we used “therapy,” “treatment,” “interven-
tion,” “drug,” and all individual names of known IOP-
SYSTEMATIC  REVIEW470 Croat Med J. 2014;55:468-80
www.cmj.hr
lowering compounds. The common search strategy was 
implemented by the two investigators independently.
selection of reviews
The reviews were included when they met the following 
criteria: a) they had to be systematic reviews with/without 
meta-analysis; b) they had to include only primary trials in 
POAG/OHT patients (ie, at least 85% POAG/OHT patients in 
the trial), or it could be verified that at least 85% of the pa-
tients across the included primary trials were POAG/OHT 
patients; c) they had to evaluate the efficacy and/or safe-
ty of mono-compound topical IOP-lowering medications. 
Systematic reviews/meta-analyses focused exclusively on 
combinational treatment modalities (unfixed or fixed com-
binations) were not included. After removal of duplicate 
publications, studies were screened based on titles and ab-
stract to select those for full text assessment of eligibility. 
Reviews were selected independently by the two investi-
gators and disagreements were resolved by a consensus.
Data abstracting
Two investigators independently abstracted the selected 
reviews. Collection forms were compared and disagree-
ments resolved by a consensus. The following character-
istics were recorded: search strategy particulars, study se-
lection criteria, declared purpose of the review, number 
of included trials and patients, evaluated treatments, pair-
wise comparisons, assessed outcomes, quality assessment 
of primary trials, methods for data pooling, reporting on 
heterogeneity, exploration of heterogeneity, evaluation of 
publication bias, presentation of primary study data, sen-
sitivity analyses, and funding source. Meta-analysis results 
were also extracted and assessed for consistency and pre-
cision.
assessment of methodological quality of reviews
Methodological quality of the included reviews was as-
sessed independently by the two investigators using the 
Figure 1. PrisMa flow-chart of the study selection process.
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AMSTAR checklist (26). This validated tool assesses 11 
items formulated as questions pertaining to quality (26) 
and each may be answered as “Yes,” “No,” “Can’t answer (?),” 
and “Not applicable.” Only a “Yes” assigns a point to an item. 
Maximum possible score is 11. Inter-rater agreement of the 
checklist is good (26). In the present overview, discrepan-
cies between the two checklists (investigators) were found 
only in 15 (8.5%) items out of 176 assessed by each investi-
gator (16 systematic reviews ×11 items) and were resolved 
by a consensus.
synthesizing data as quality of evidence
We used the GRADE system (27) to derive the level of evi-
dence provided by each systematic review and then to de-
rive the level of evidence (based on all reviews) regarding 
individual mono-compound relationships regarding IOP-
lowering efficacy and safety. For systematic reviews/meta-
analyses, the GRADE system assigns an a priori high level 
of “quality of evidence,” and then addresses potential draw-
backs (“-1 step” if serious, “-2 steps” if very serious) regarding 
bias, inconsistency, indirectness, imprecision, and publica-
tion bias; ie, potential additional strengths (“+1 step” or “+2 
steps”) regarding the size of the effect, evidence of dose-
response, and accounting for residual confounding (27). 
The final grades of quality of evidence are “high” (strong 
confidence that the true effect lies close to the estimate 
of the effect); “moderate” (moderate confidence in the esti-
mate: the true effect is likely to be close, but there is a pos-
sibility that it is substantially different); “low” (limited confi-
dence about the estimate: the true effect may substantially 
different) and “very low” (little confidence in the effect es-
timate: the true effect is likely to be substantially different).
resulTs
selection of reviews
Of the initially identified 597 records (none by the hand 
search), 133 non-duplicates were screened and 21 re-
trieved in full text. Finally, the present overview included 
16 systematic reviews (Figure 1) (see Supplementary Table 
1 for those excluded in the last step).
Characteristics of the included reviews
Table 1 summarizes main characteristics of the 16 includ-
ed reviews. They were published between 2000 and 2010. 
Most (10/16) were focused on both efficacy and tolerabil-
ity/safety (as a secondary objective) (29,31,33-38,40,43), five 
addressed only efficacy (28,30,32,39,42), and one addressed 
exclusively local tolerability, specifically conjunctival hyper-
emia (41). Two reviews (42,43) synthesized data using net-
work meta-analysis, whereas others were declared as “clas-
sical” meta-analyses. Two authors published more than one 
review [Cheng et al (35,38,39)], even on the same primary 
studies [Van der Valk et al (30,42)]. The assessed treatments 
and primary study selection criteria varied. One network 
meta-analysis (42) aimed to assess “the most common-
ly prescribed mono-compounds,” whereas the other (43) 
evaluated also combination treatments, but the focus of 
the present overview was on mono-compounds. Another 
review (33) also addressed mono-compound and “adjunc-
tive treatment” comparisons, but was included as it provid-
ed the most comprehensive comparison between latano-
prost and brimonidine. Two further reviews evaluated “all 
most commonly prescribed mono-compound treatments” 
(30,39). Overall, the following mono-compound medica-
tions were evaluated through different modes of mutual 
comparisons: placebo; beta-blockers (BB) – timolol (always 
as an individual compound), betaxolol (as an individual 
compound or referred to as “other BB” together with eg, car-
teolol, levobunolol, and others); alpha2-receptor agonists – 
brimonidine; carbonic anhydrase inhibitors (CAI) – brinzol-
amide and dorzolamide (as individual compounds or as “CAI 
as a group”); and prostaglandin analogues (PGAs) – latano-
prost, travoprost, and bimatoprost. One review (39) explic-
itly included only trials in normal-tension glaucoma (NTG) 
patients. Considering the inclusion/exclusion criteria for pri-
mary studies combined with the displayed structures of the 
embraced patients (in the primary studies), it is safe to con-
clude that all other reviews assessed the treatments in the 
setting of (predominantly) POAG/OHT. Only 1/16 reviews 
included, among the primary studies, several non-random-
ized trials (4/16) (40). All other primary trials in all other re-
views were RCTs, although 2 reviews intended to include 
also quasi-randomized trials (33,37). Two reviews (32,43) did 
not assess primary study quality and the others implement-
ed different tools, most commonly the Jadad score.
Quality of the included reviews
The AMSTAR checklist for the included reviews is shown 
in Table 2. Rationale for the assigned scores is elaborated 
in more detail in Supplementary Table 2. Some elements 
of scoring are self-evident (eg, whether conflict of inter-
est was declared or publication bias assessed), but some 
require clarifications, particularly if “N” or “?” was assigned 
to an item. We assigned “?” for the first AMSTAR item 
to four studies due to discrepancies between the 
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Table 1. Main characteristics of the included reviews (in chronological order)*†
reference objective Criteria for primary studies studies (k), patients (n) Primary study assessments
Einarson 
2000 (28)
Indirectly compare 
LAT with BRIM for 
IOP reduction in 
POAG.
RCT, English language. POAG 
with IOP≥20 mm Hg. At least one 
arm includes LAT or BRIM. Peak, 
trough or diurnal IOP; duration 
3-12 months.
k = 9 (DB, parallel), none 
comparing LAT to BRIM. LAT: 
k = 6; BRIM: k = 3.
Quality: Jadad score. Efficacy: ΔIOP vs 
baseline and % with controlled IOP for 
LAT and BRIM as individual treatments. 
Safety: not assessed. Random-effects.
Zhang
2001 (29)
Compare LAT with 
TIM for IOP reduc-
tion and safety in 
OAG/OHT.
RCT. OAG/OHT. Directly compare 
LAT and TIM.
k = 11 (10 DB, 1 SB; 7 parallel, 
4 crossover); n = 1256; 410 
POAG, 465 OHT, 137 OAG.
Quality: Jadad score. Efficacy: ΔIOP vs 
baseline at 4 time points. Safety: local, 
systemic, AE withdrawals. Random or 
fixed-effect.
van der Valk 
2005 (30)
Estimate IOP 
reduction at peak 
and trough by the 
most commonly 
prescribed mono 
compounds in 
POAG-HTG/OHT.
RCT, English, German, Dutch or 
French language. POAG-HTG or 
OHT. Compare (any): Placebo; TIM 
0.5% bid; BET 0.5% bid; BRIM 0.2% 
bid; DORZ 2.0% bid; BRINZ 1.0% 
tid; LAT 0.005% qd; TRAV 0.004% 
qd; BIMA 0.03% qd.
k = 27, n = 6053 for peak and 
6861 for trough IOP. Placebo 
k = 3; BET k = 5; TIM k = 15; 
BIMA k = 6; LAT k = 12; TRAV 
k = 5; BRIM k = 4, BRINZ k = 1, 
DORZ k = 6.
Quality: Delphi score. Efficacy: absolute 
and relative ΔIOP vs baseline for peak 
and trough for each individual treat-
ment; 1-6 months pooled as 1 time 
point. Safety: not assessed. Random-
effects.
Li
2006 (31)
Compare TRAV 
with LAT, BIMA 
and TIM for IOP re-
duction and safety 
in OAG/OHT.
RCT, English or Chinese language. 
OAG or OHT; Compare TRAV vs 
other PGA or TIM. Report IOP or 
AEs.
k = 12 (parallel, 8 DB, 4 SB);
n = 3048, 2060 POAG, 840 
OHT, 114 other.
TRAV 0.004% vs TIM k = 4; 
TRAV 0.004% vs BIMA k = 5; 
TRAV 0.004% vs LAT k = 5.
Quality: Cochrane tool for risk of bias. 
Efficacy: ΔIOP vs baseline; 8/12 trials ITT 
analysis. Safety: local. Random or fixed-
effect.
Denis
2007 (32)
Compare TRAV 
with LAT and BIMA 
for IOP reduction 
in OAG/OHT.
RCT, parallel, English of French 
language. OAG or OHT. Any 
comparison of TRAV, LAT, BIMA; 
Report on IOP.
k = 9; n = 1318, 378 OHT, 919 
OAG, 21 other
Comparing all 3 (three-arm 
trials) k = 2
Comparing any two (two-
arm trials) k = 7.
Quality: not assessed. Efficacy: IOP at 
study end (average) and % responding 
for each individual treatment. Safety: Not 
assessed. Random-effects.
Fung
2007 (33)
Compare LAT with 
BRIM for IOP re-
duction and safety 
in OAG/OHT.
RCT or quasi-RCT. OAG/NTG/OHT. 
Compare LAT to BRIM; adjunctive 
treatment possible. Duration ≥1 
month. Reports on efficacy or 
safety.
k = 15 (all RCT, 11 parallel, 
4 crossover; 4 DB, 7 SB, 4 
unknown). n = 1824, 1299 
OAG, 390 OHT, 64 NTG, 60 
other. Mono-treatment k = 9; 
adjunctive treatment k = 6.
Quality: Allocation concealment, blind-
ing and IOP measurement method.  
Efficacy: ΔIOP vs baseline, peak or diur-
nal. 5/15 trials ITT analysis. Safety: local 
and systemic. Random-effects.
Aptel
2008 (34)
Compare BIMA, 
LAT and TRAV for 
IOP reduction and 
safety in POAG/
OHT.
RCT, DB. POAG or OHT>90%. Com-
pare LAT 0.005%, TRAV 0.004% or 
BIMA 0.03% 1 drop/d between 6 
and 10 pm Report diurnal IOP and 
conjunctival hyperemia. Duration 
1-6 months.
k = 8 (parallel). n = 1610;
LAT vs BIMA k = 4; TRAV vs 
BIMA k = 2; LAT vs TRAV k = 1; 
LAT vs TRAV vs BIMA k = 1.
Quality: Jadad score. Efficacy: Δ IOP vs 
baseline (4 daily values: 8 am, 12 noon, 
4 pm, 8 pm separately), all trial duration 
as one time point. Safety: conjunctival 
hyperemia. Fixed-effect.
Cheng
2008 (35)
Compare BIMA 
with LAT for IOP 
reduction and 
safety in glau-
coma/OHT.
RCT. Glaucoma or OHT, NTG 
excluded. Directly compare LAT 
and BIMA. Report on IOP reduc-
tion or % patients achieving the 
target IOP.
k = 13 (5 DB, 8 SB, 10 parallel, 
3 crossover).
n = 1302; 754 POAG, 327 OHT, 
211 other.
LAT 0.005% vs BIMA 0.03%; 
1 × evening
Quality: Jadad score. Efficacy: Δ IOP vs 
baseline (morning/diurnal) or % patients 
achieving IOP≤17; 3 different time points. 
Safety. local. Random-effects. ITT basis.
Hodge
2008 (36)
Compare PGAs 
with BRIM and 
DORZ for IOP re-
duction and safety 
in OAG/OHT.
RCT, English language. OAG/OHT, 
ACG excluded. Compare PGAs 
and BRIM or DORZ.
k = 7 (parallel); n = 1131, 418 
POAG, 555 OHT, 60 other, 98 
unknown. LAT vs BRIM k = 3 
(+1 safety); LAT vs DORZ k = 3
Quality: Jadad score. Efficacy: Δ IOP 
vs baseline at 3 months. 2/7 trials ITT. 
Safety: local, AE withdrawals. Random or 
fixed-effect.
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Loon
2008 (37)
Compare TIM with 
BRIM for IOP re-
duction and safety 
in glaucoma.
RCT, pseudo-RCT. Glaucoma. Di-
rectly compare TIM 0.5% to BRIM 
0.2%. Report on IOP and safety, 
≥1 month.
k = 10 (all RCT, 7 DB, 1 
open, 2 unknown); 8 used 
for quantitative synthesis; 
n = 2387, 1442 OAG, 877 OHT, 
68 other.
Quality: Allocation concealment, blind-
ing, withdrawals, ITT/LOCF. Efficacy: Δ 
IOP vs baseline (peak or mean). 8/10 
trials ITT analysis. Safety: local, systemic. 
Random-effects.
Cheng
2009a (38)
Compare TRAV 
and LAT for IOP re-
duction and safety 
in OAG/OHT.
RCT. OAG/OHT with lOP>21 mm 
Hg, NTG/ACG excluded. Compare 
TRAV 0.004% to LAT 0.005% once 
daily. Report on IOP at 9 am and/
or 5 pm
k = 17 (9 DB, 8 SB, 13 parallel, 
4 crossover),
n = 1491; 966 OAG, 379 OHT, 
146 other.
Quality: Jadad score. Efficacy: Δ IOP vs 
baseline (separately 9 am and 5 pm) at 
5 different time points. 6/17 trials ITT 
analysis. Safety: local and AE withdraw-
als. Random-effects.
Cheng
2009b (39)
Estimate IOP 
reduction by the 
most commonly 
prescribed mono 
compounds in 
NTG.
RCT, any language; Advanced 
NPG.
Compare (any): Placebo, BET 
0.25/0.5% bid, TIM 0.5% bid, 
DORZ 0.2% tid, BRINZ 1.0% tid, 
BRIM 0.2% bid, LAT 0.005% qd, 
TRAV 0.004% qd, BIMA 0.03% qd. 
Report absolute and relative IOP 
reduction.
k = 15 (5 DB, 6 SB, 4 open, 
5 parallel, 10 crossover); 
n = 450.
Quality: Delphi score. Efficacy: absolute 
and relative ΔIOP vs baseline for peak, 
trough and diurnal curve for each indi-
vidual treatment (0.5-2 months) as 1 time 
point. Safety: not assessed. Random-
effects.
Ejawo
2009 (40)
Compare BIMA, 
LAT and TRAV for 
IOP reduction and 
safety in POAG/
OHT.
RCT, excluded dose-finding, cross-
over and short-term. POAG/OHT. 
Any comparison between TRAV 
0.004%, LAT 0.005% and BIMA 
0.03%. Report on IOP and AEs.
k = 16 (4 non-RCT, unknown 
blinding), n = 2674, 1705 
POAG, 727 OHT, 242 other. 
TRAV vs LAT k = 9; TRAV vs 
BIMA k = 8; LAT vs BIMA k = 8; 
>2 arms k = 5.
Quality: randomization, allocation 
concealment, ITT, blinding. Efficacy: IOP 
(morning) at study end (3-12 months), 
6/16 trials ITT analysis. Safety: conjuncti-
val hyperemia. Random-effects.
Hornubia 
2009 (41)
Compare LAT with 
BIMA and TRAV 
for conjunctival 
hyperemia in 
glaucoma/OHT.
RCT, English language. Glaucoma/
OHT. Any comparison between 
LAT, BIMA or TRAV reporting on 
conjunctival hyperemia.
k = 13 (10 parallel, 3 cross-
over); n = 2222; 1364 OAG, 
678 OHT and 180 other. LAT 
vs BIMA k = 8, LAT vs TRAV 
k = 6, 3 arms k = 1.
Quality: Jadad score. Efficacy: Not as-
sessed.
Safety: Conjunctival hyperemia. Fixed 
and random-effects.
v.d.Valk 
2009 (42)
Estimate IOP 
reduction at peak 
and trough by the 
most commonly 
prescribed mono 
compounds in 
POAG-HTG/OHT 
by MTC.
RCT, English, German, Dutch or 
French language. POAG-HTG or 
OHT. Compare (any): Placebo; TIM 
0.5% bid; BET 0.5% bid; BRIM 0.2% 
bid; DORZ 2.0% bid; BRINZ 1.0% 
tid; LAT 0.005% qd; TRAV 0.004% 
qd; BIMA 0.03% qd.
k = 27, n = 6053 for peak and 
6861 for trough IOP. Placebo 
k = 3; BET k = 5; TIM k = 15; 
BIMA k = 6; LAT k = 12; TRAV 
k = 5; BRIM k = 4, BRINZ k = 1, 
DORZ k = 6.
Quality: Delphi score. Efficacy: abso-
lute and relative ΔIOP vs baseline for 
peak and trough using timolol as a 
reference;1-6 months pooled as 1 time 
point. Safety: not assessed. Random-
effects.
Orme
2010 (43)
Compare IOP 
reduction and 
conjunctival 
hyperemia of dif-
ferent treatments 
in POAG/OHT by 
MTC.
RCT, English language, ≥20 pa-
tients. POAG/OHT, excluded ACG 
& secondary. Include a PGA in at 
least one arm.
MTC Efficacy: k = 18; n = 2943; 
MetaReg Efficacy k = 73, 
n = 11519; MTC Safety: k = 72. 
Evaluated treatments: TIM, 
LAT- TlM, CAI-TIM, TRAV-TIM, 
BIMA, TRAV, LAT, CAI, Other 
UC, Other BB, Placebo.
Quality: Not assessed. Efficacy: MTC 
for 3-month outcomes - absolute IOP; 
predicted probability of IOP<20 mm Hg 
or ≥20% reduction vs baseline and NNTB 
vs timolol. Safety: MTC of % patients with 
conjunctival hyperemia and NNTH vs 
Placebo. Random-effects.
*all individual studies included men and women, but their proportions varied.
†abbreviations related to methodology: rCT – randomized controlled trial; Db – double-blind; sb – single blind; iTT – intention–to-treat; loCF 
– last observation carried-forward; PP – per-protocol; nnTb – number needed to treat to benefit; nnTh – number needed to treat to harm; 
Metareg – meta-regression analysis; MTC – random-effects mixed treatment comparisons (or network meta-analysis);
abbreviations related to disease: Poag – primary open angle glaucoma; ohT – ocular hypertension; nTg – normal tension glaucoma; oag 
– open angle glaucoma; PDg – pigment dispersion glaucoma; aCg – angle closed glaucoma; hTg – high tension glaucoma; ioP – intraocular 
pressure; aes – adverse events;
abbreviations related to drugs: Pgas – prostaglandin analogues; Cai – carbonic anhydrase inhibitors; bb – beta-blockers; uC – unfixed combina-
tions; laT – latanoprost; biMa – bimatoprost; TraV – travoprost; briM – brimonidine; TiM – timolol; beT – betaxolol; DorZ – dorzolamide; brinZ 
– brinzolamide; qd – once a day; bid – twice a day; tid – three times a day.
Table 1. Continued. Main characteristics of the included reviews (in chronological order)*†
reference objective Criteria for primary studies studies (k), patients (n) Primary study assessments
SYSTEMATIC  REVIEW474 Croat Med J. 2014;55:468-80
www.cmj.hr
declared aims and actually implemented procedures. For 
example, two reviews (30,39) intended to evaluate a large 
number of individual treatments without defining the 
method, but did not use network meta-analysis (for details 
see Supplementary Table 2). The reason for assigning “?” to 
the fifth AMSTAR item in most of the reviews was the fact 
that the lists of the included but not the lists of excluded 
primary trials were reported. Reviews that did not consider 
primary trial quality when drawing conclusions from the 
meta-analytical results were assigned an “N” for the eighth 
AMSTAR item. However, the major flaws were related to 
methods of data pooling (see Supplementary Table 2 for 
details): only 4 reviews used fully correct methods; 5 re-
views were assigned a “?” as they alternately (and inappro-
priately) used fixed and random-effects pooling without 
clear criteria; and 7 reviews used explicitly erroneous data 
pooling methods that resulted in non-randomized com-
parison and/or erroneous variance calculation.
Quality of evidence
The highest level of quality of evidence achieved was 
“moderate” and was attained by 5 reviews (Table 3). Li et al, 
2006 (31) and Aptel et al, 2008 (34) were downgraded by 
1 for imprecision because certain comparisons between 
pairs of treatments were based on only 1-2 primary trials 
and/or a small number of patients, resulting in very wide 
confidence intervals. Fung et al, 2007 (33) and Hornubia 
et al, 2009 (41) were downgraded by 1 for limitations/bias 
since they included only a few double-blind trials and 
intent-to-treat analysis in primary studies was low or un-
known. In addition, the unit-of-analysis issue (unclear han-
dling of multi-arm and crossover trials) was highly suspect-
ed in Hornubia et al, 2009 (41). Orme et al, 2010 (43) was 
downgraded by 1 for indirectness since some of the effi-
cacy comparisons in the assessed network were predomi-
nantly or exclusively indirect. Details on rationale for qual-
ity assessment of these and all other reviews are available 
in Supplementary Table 2.
relationship between different compounds
Only the reviews achieving moderate level of quality of ev-
idence (31,33,34,41,43) were considered for evaluation of 
relationship between treatments.
Efficacy. Based on IOP reduction after 3 months of treat-
ment, Orme et al (43) ranked 6 mono-compound medica-
Table 2. Quality of the included reviews based on the aMsTar (26) checklist*
einarson
2000
 (28)
Zhang 
2001
 (29)
v.d Valk 
2005
 (30)
li 
2006
 (31)
Denis 
2007
 (32)
Fung 
2007
 (33)
aptel 
2008
 (34)
Cheng 
2008
 (35)
hodge 
2008
 (36)
loon 
2008
 (37)
Cheng 
2009a
 (38)
Cheng 
2009b 
(39)
ejawo 
2009
 (40)
hornubia 
2009
 (41)
v.d. Valk 
2009
 (42)
orme 
2010
 (43)
Design “a priori”? ? Y ? Y Y Y Y Y Y Y Y ? ? Y Y Y
Duplicate selection/
extraction?
Y Y Y Y N Y Y Y Y Y Y Y Y Y Y‡ ?
Comprehensive 
search?
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y‡ Y
Publication status 
clear?
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y‡ Y
List included/ex-
cluded provided?†
? ? ? Y ? ? ? Y ? ? ? ? ? Y ? Y
Study characteris-
tics provided?
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y‡ Y
Quality assessed? Y Y Y Y N Y Y Y Y Y Y Y Y Y Y‡ N
Quality accounted 
for conclusions?
Y Y Y N N Y Y N Y Y Y Y Y N N N
Appropriate meth-
od for pooling?
N N N ? N Y ? ? Y N N N Y ? ? Y
Publication bias 
assessed?
N N Y Y Y Y Y N N Y Y Y Y Y ? Y
Conflict of interest 
declared?
Y N Y Y Y Y Y Y Y N N Y Y Y Y Y
AMSTAR score 7 7 8 9 6 10 9 8 9 8 8 8 9 9 7 8
*abbreviations: Y – yes; n – no; ? – can’t tell; na – not applicable.
†all reviews reported on included studies, but only 3 reported also on excluded studies. hence, most reviews failed to meet this quality criterion.
‡Described in the previous publication [v.d. Valk 2005 (30)].
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tions in the following order (most effective to least effective): 
bimatoprost, latanoprost, travoprost, CAI group, BB group 
without timolol, timolol. However, many of the differences 
between treatments were very small and although statisti-
cally significant they did not appear practically relevant. Ta-
ble 4 summarizes point-estimates of pair-wise differences in 
IOP reduction reported by Orme et al (43). Assuming that 
the limits of -1.0 to +1.0 mm Hg for IOP reduction are reason-
able limits of therapeutic equivalence (40), the three PGAs 
appear to be equivalent. In a series of pair-wise comparisons, 
Aptel et al (34) calculated somewhat larger differences be-
tween bimatoprost and latanoprost, and between bimato-
prost and travoprost – but still, all were well within the -1.0 to 
+1.0 range. Li et al (41) compared travoprost to bimatoprost 
and reported zero difference (point-estimate 0.08 mm Hg), 
while the difference between travoprost and latanoprost 
was -0.57 mm Hg. Despite these variations, it appears rea-
sonable to conclude that the IOP-reducing potential of the 
three PGAs is not relevantly different.
According to Orme et al (43), PGAs are more effective than 
other evaluated drugs, but in this respect they should be 
considered individually. Bimatoprost was relevantly supe-
rior to CAI, BB other than timolol, and timolol, whereas la-
tanoprost and travoprost showed a relevant difference 
only in relation to timolol (Table 4). The findings of Li et al 
(41) confirmed the size of the difference between travo-
prost and timolol, whereas Fung et al (33) reported a rel-
evant difference between latanoprost and brimonidine 
(point-estimate 1.10 mm Hg). Finally, according to Orme 
et al (43), CAI as a group, timolol, and other BB did not rel-
evantly differ regarding their IOP-reducing potential (Table 
4). However, these relationships were estimated practically 
exclusively through indirect comparisons and we found no 
other evidence of at least moderate quality that would re-
late these treatments to each other.
Tolerability/safety. The only adverse event addressed by all 5 
reviews was conjunctival hyperemia. The most comprehen-
Table 3. Quality of evidence provided by individual reviews based on the graDe (27) evaluation system
einarson
2000
 (28)
Zhang 
2001
 (29)
v.d Valk 
2005
 (30)
li 2006
 (31)
Denis 
2007
 (32)
Fung 
2007
 (33)
aptel 
2008
 (34)
Cheng 
2008
 (35)
hodge 
2008
 (36)
loon 
2008
 (37)
Cheng 
2009a
 (38)
Cheng 
2009b 
(39)
ejawo 
2009
 (40)
hornubia 
2009
 (41)
v.d.Valk 
2009
 (42)
orme 
2010
 (43)
Limitations/
bias
-1 -1 -1 Minor -2 -1 Minor -1 -1 -1 -1 -1 -2 -1 -1 Possible
Inconsistency Minor -1 Minor Minor -1 Mi-
nor
Minor -1 Some -1 Minor Minor Some No Minor No
Indirectness -2 Direct -2 Direct -2 Di-
rect
Direct Direct Direct DirectDirect -2 Direct Direct -1 -1
Imprecision Minor Minor Minor -1 Minor Mi-
nor
-1 Some -1 Minor -1 Some Minor Minor Minor Minor
Publication 
bias
Unlikely Un-
likely
Unlikely Un-
likely
Un-
likely
Un-
likely
Un-
likely
Un-
likely
Un-
likely
Un-
likely
Un-
likely
Un-
likely
Un-
likely
Unlikely Pos-
sible
Unlikely
Quality of 
body of 
evidence*
+
Very low
++
Low
+
Very 
low
+++
Moder-
ate
-
Very 
low
+++
Mod-
erate
+++ 
Mod-
erate
++
Low
++
Low
++
Low
++
Low
+
Very 
low
++
Low
+++
Moderate
++
Low
+++
Moder-
ate
*This is judged in respect to the primary research question posted in each review. see Materials and Methods for the graDe system levels of quality 
of evidence.
Table 4. Point-estimates of differences (mmhg) between pairs of treatments in ioP reduction at 3 months vs baseline as determined 
in a network meta-analysis by orme et al (43). a positive value indicates a greater reduction by the “row drug” vs “column drug” and a 
negative value indicates the opposite. bolded are values that exceed a difference of ±1.0 mm hg and underlined are the differences 
close to this limit*†
bimatoprost latanoprost Travoprost Cai as a group bb w/o timolol Timolol
Bimatoprost  —  0.45  0.47  0.97 1.09 1.41
Latanoprost -0.45  —  0.02  0.52  0.64 0.96
Travoprost -0.49 -0.02  —  0.50  0.62 0.94
CAI as a group -0.97 -0.52 -0.50  —  0.12 0.44
BB w/o timolol -1.09 -0.64 -0.62 -0.12  — 0.32
Timolol -1.41 -0.96 -0.94 -0.44 -0.32  —
*We assumed that the limits of -1.0 to +1.0 mm hg for a difference in ioP reduction could be reasonably accepted as limits of equivalence (40).
†ioP – intraocular pressure; bb – beta blockers; Cai – carbonic anhydrase inhibitors; w/o – without.
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sive assessment was that by Orme et al (43), ie, through a 
network meta-analysis including 73 RCTs. Ranking of mono-
compound drugs from the lowest to the highest incidence 
of conjunctival hyperemia was: timolol, dorzolamide, brimo-
nidine, latanoprost, travoprost, and bimatoprost. Betaxolol 
was also ranked, but based only on one trial arm with only 
34 patients (43). Table 5 summarizes point-estimate odds ra-
tios (ORs). Odds of hyperemia with latanoprost were around 
3-fold and around 5-fold lower than with travoprost and bi-
matoprost, respectively (Table 5). Similar estimates were re-
ported by Hornubia et al (41), whereas estimates provided 
by Aptel et al (34) and Li et al (41) were somewhat smaller 
(1.5-2.0-fold lower odds). While Orme et al (43) indicated no 
relevant difference between travoprost and bimatoprost 
(Table 5), Aptel et al (34) and Li et al (41) reported a signifi-
cantly lower incidence with travoprost – ORs around 0.86 
(34) and around 0.65 (41), respectively. Overall, it seems rea-
sonable to conclude that latanoprost conveys the lowest 
risk of conjunctival hyperemia among PGAs, whereas evi-
dence on travoprost vs bimatoprost is inconclusive.
The review by Orme et al (43) was the only evidence of at 
least moderate quality about safety comparison between 
non-PGA compounds and indicated no relevant differ-
ence between timolol, brinzolamide, and brimonidine in 
respect to conjunctival hyperemia (Table 5). It also demon-
strated that, in this respect, bimatoprost was considerably 
worse than any of these drugs, whereas latanoprost and 
travoprost were worse than timolol (Table 5). Data from Li 
et al (41) and Fung et al (33) confirmed higher incidence 
with travoprost vs timolol (OR 11.5) and no difference be-
tween latanoprost and brimonidine (relative risk around 
unity), respectively.
Fung et al (33) compared latanoprost to brimonidine in re-
spect to a number of AEs besides hyperemia (eg, eyelid 
disorders, visual disturbances, keratopathy, dry eye, hyper-
trichosis, fatigue, headache) indicating no difference be-
tween the two. Li et al (41) indicated considerably higher 
odds of eye-lash changes and iris pigmentation with tra-
voprost as compared to timolol or latanoprost. However, 
considering the specifics of the systematic reviews of AEs 
(25), in respect to these assessments quality of evidence 
provided by the two reviews was less than moderate: a) 
none of the included primary trials was specifically de-
signed to assess safety/tolerability; b) neither review evalu-
ated the quality of primary trials specifically in respect to 
AEs recording, evaluation, and reporting; c) data on most 
of the outcomes were available from only a few trials and 
prevalence of “zero event cells” was rather high.
Combining efficacy and tolerability. None of the five re-
views (31,33,34,41,43) attempted to rank treatments based 
on a composite criterion combining efficacy and tolerabil-
ity/safety. Data suggest that among PGAs, latanoprost has 
the most favorable trade-off between efficacy and toler-
ability. However, none of the presented reviews includes 
trials with preservative-free PGA formulations that have re-
cently emerged (44-48), and this conclusion might change 
in the near future.
The existing evidence does not point to any relevant dif-
ference regarding efficacy and safety of non-PGA com-
pounds – dorzolamide, brimonidine, timolol, and “other” 
BB. Compared to PGAs, and in addition to (at least some-
what) lower efficacy, they are limited by the fact of twice 
or thrice daily administration (vs once daily). It appears 
reasonable to consider them as alternative options when 
PGAs are contraindicated or not tolerated.
DisCussion
overall completeness and applicability of evidence
The present work addressed only a segment of pharmaco-
logical treatment of glaucoma, ie, only POAG/OHT and only 
Table 5. Differences between pairs of treatments in incidence of conjunctival hyperemia as determined in a network meta-analysis 
by orme et al (43). Differences are expressed as odds ratios: values >1.0 indicate a greater incidence for the “row drug” vs “column 
drug,” and values <1.0 indicate the opposite
Timolol Dorzolamide brimonidine latanoprost Travoprost bimatoprost
Timolol  —  ∼ 1*  ∼ 1* 0.56 0.18 0.11
Dorzolamide  ∼ 1*  —  ∼ 1*  ∼ 1*  ∼ 1* 0.22
Brimonidine  ∼ 1*  ∼ 1*  —  ∼ 1*  ∼ 1* 0.21
Latanoprost 1.78  ∼ 1*  ∼ 1*  — 0.32 0.21
Travoprost 5.55  ∼ 1*  ∼ 1* 3.12  —  ∼ 1*
Bimatoprost 9.09 4.54 4.76 4.76  ∼ 1*  —
*odds ratios around 1 ( ~ 1) indicate a lack of a statistically significant difference (95% confidence intervals around the odds ratio extend from below 
to above unity).
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mono-compound drugs, and aimed to address evidence 
of their relative efficacy and tolerability specifically through 
evaluation of systematic review/meta-analysis and not in-
dividual trials. These choices appear reasonable: a) POAG/
OHT are the most prevalent conditions requiring IOP-re-
ducing medications; b) mono-compound medications are 
the recommended first-line treatments; c) systematic re-
views are considered the highest level of evidence based 
on filtered information and have been regularly published 
in the field. The choice of the method resulted in the fact 
that all currently most commonly used mono-compound 
drugs were embraced by the present evaluation, but some 
older individual drugs or drug classes (eg, older alpha2-
agonists, BB, or CAI; miotics) and newer products like pre-
servative-free formulations were not – simply due to the 
fact that so far they have not been subject to systematic 
reviews. However, these facts do not pose any major limi-
tation to the present work. Over the years, the evaluated 
drugs have positioned themselves as preferable to most of 
the older ones and have become standards. In respect to 
new developments, they could be considered as “of pro-
gressively declining interest.” However, assessment of their 
relative efficacy and safety is of practical relevance for at 
least two reasons: a) full evaluation of newer or emerging 
treatments will take some time; b) new products, regard-
less of whether conveying conceptually new treatment 
options or “just” potential improvements to known strate-
gies, are inevitably more expensive, particularly consider-
ing the fact that “standards” are already available in generic 
versions. While new options might eventually prove to be 
highly cost-effective, optimization of the use of pharmaco-
logical armamentarium at hand seems a reasonable effort.
Quality of evidence
Our research question was relatively complex as it per-
tained to a number of individual mono-compound drugs 
and also to both efficacy and safety. None of the assessed 
reviews provided high quality evidence and five provided 
evidence of moderate quality. However, this judgment 
does not apply uniformly to all of the addressed topics. 
A moderate quality body of evidence was available for a) 
comparison between PGAs – latanoprost, bimatoprost, 
and travoprost in respect to efficacy and incidence of con-
junctival hyperemia; b) comparison between the three 
PGAs and non-PGA compounds – timolol, other BB, bri-
monidine, and CAI (dorzolamide, or combined data for 
dorzolamide and brinzolamide) in respect to efficacy and 
conjunctival hyperemia incidence. Evidence about com-
parison between non-PGA compounds regarding efficacy 
and evidence regarding any other safety/tolerability as-
pect apart from conjunctival hyperemia incidence was of 
less than moderate quality.
Potential biases in the overview process
All conclusions on mutual treatment comparisons in the 
present overview are based on evidence of moderate qual-
ity. Where this level of quality was not available, no con-
clusions were drawn. In this way, the conclusions are fairly 
protected from biases that could have been introduced 
by the primary trials or systematic review methodological 
flaws. At the overview level, we could have introduced bias 
by omission of one systematic review that was written in 
Chinese. Another source of bias could be the fact that we 
did not include individual studies, ie, not even those pub-
lished since the last systematic review on the topic.
agreements and disagreements with other studies or 
reviews
To the best of our knowledge, this is the only overview 
of systematic reviews dealing with efficacy and safety of 
mono-compound IOP-lowering drugs in POAG/OHT.
Conclusions
Implications for practice. Over the years, PGAs have 
emerged as preferred mono-compound treatments in 
POAG/OHT. The present overview indicates that among 
PGAs, latanoprost has the most favorable trade-off be-
tween efficacy and tolerability. Use of travoprost or bi-
matoprost as a first-line treatment of POAG/OHT is not very 
likely to result in a relevantly better efficacy, but is highly 
likely to result in conjunctival hyperemia, a common cause 
of patient-driven discontinuation of treatment. Non-PGA 
treatments should be considered as alternatives when 
PGAs are contraindicated or not tolerated. While tradition-
ally BB, particularly timolol, have been considered as the 
major non-PGA treatment option, there is no clear-cut evi-
dence that supports preference of timolol over CAI or bri-
monidine either regarding efficacy or regarding safety.
Implications for research. The medications addressed 
in the present overview represent the current standard 
choice of mono-compound IOP-lowering drugs and are 
likely to remain relevant for at least some time in the fu-
ture. Still, certain questions about their relative efficacy 
and tolerability cannot be answered with certainty 
since the body of available evidence does not meet 
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the criteria of at least moderate quality. With the on-going 
pharmacological developments in the field, these drugs 
are not very likely to be engaged in major primary trials in 
the future. However, the number of the existing primary 
trials – those addressed in the overviewed systematic re-
views and those published over the last few years (or still 
on-going) – is considerable, and many of those are actual-
ly high-quality individual trials. Under such circumstances, 
new developments in the field of research synthesis seem 
a convenient and powerful tool for converting the existing 
primary data into evidence of relevant quality. Many of the 
reviews assessed in the present work suffered from serious 
methodological limitations, but they could all be avoided. 
It appears likely that adequate quality of evidence could 
be generated with improved assessment of quality of the 
primary trials, inclusion of only high-quality primary data, 
appropriate assessment of data combinability, sensitivity 
analyses, and appropriate implementation of “standard” 
and novel (network) data-pooling techniques.
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